IVexSol is a lentiviral vector production platform that supplies a consistent source of vectors for successful gene therapy programs.
iVexSol has raised $23.8M in total funding. The most recent round was Series A. The last funding was announced in January 2023.
iVexSol's investors include Bristol-Myers Squibb, Charles River Laboratories International, Casdin Capital, Massachusetts Life Sciences Center, BioLife Solutions.
iVexSol is headquartered in Lexington, United States.
IVexSol is a lentiviral vector production platform that supplies a consistent source of vectors for successful gene therapy programs.
iVexSol is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"iVexSol — Funding & Investors." VCBacked, January 26, 2023, https://www.vcbacked.co/company/ivexsol. Accessed July 23, 2026.
VCBacked. (2023). iVexSol — Funding & Investors. Retrieved July 23, 2026, from https://www.vcbacked.co/company/ivexsol
{{cite web |title=iVexSol — Funding & Investors |url=https://www.vcbacked.co/company/ivexsol |website=VCBacked |access-date=July 23, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated